CN106456629A - 用于运动机能亢进性运动障碍的治疗的vmat2抑制剂 - Google Patents

用于运动机能亢进性运动障碍的治疗的vmat2抑制剂 Download PDF

Info

Publication number
CN106456629A
CN106456629A CN201580023821.XA CN201580023821A CN106456629A CN 106456629 A CN106456629 A CN 106456629A CN 201580023821 A CN201580023821 A CN 201580023821A CN 106456629 A CN106456629 A CN 106456629A
Authority
CN
China
Prior art keywords
htbz
methods
dimethoxy
pyrido
hexahydro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201580023821.XA
Other languages
English (en)
Chinese (zh)
Inventor
克里斯托弗·F·奥布赖恩
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Neurocrine Biosciences Inc
Original Assignee
Neurocrine Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurocrine Biosciences Inc filed Critical Neurocrine Biosciences Inc
Priority to CN202011483141.5A priority Critical patent/CN112741836A/zh
Priority to CN202011483135.XA priority patent/CN112741835A/zh
Publication of CN106456629A publication Critical patent/CN106456629A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychology (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CN201580023821.XA 2014-05-06 2015-05-06 用于运动机能亢进性运动障碍的治疗的vmat2抑制剂 Pending CN106456629A (zh)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN202011483141.5A CN112741836A (zh) 2014-05-06 2015-05-06 用于运动机能亢进性运动障碍的治疗的vmat2抑制剂
CN202011483135.XA CN112741835A (zh) 2014-05-06 2015-05-06 用于运动机能亢进性运动障碍的治疗的vmat2抑制剂

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461989240P 2014-05-06 2014-05-06
US61/989,240 2014-05-06
PCT/US2015/029519 WO2015171802A1 (en) 2014-05-06 2015-05-06 Vmat2 inhibitors for the treatment of hyperkinetic movement disorders

Related Child Applications (2)

Application Number Title Priority Date Filing Date
CN202011483141.5A Division CN112741836A (zh) 2014-05-06 2015-05-06 用于运动机能亢进性运动障碍的治疗的vmat2抑制剂
CN202011483135.XA Division CN112741835A (zh) 2014-05-06 2015-05-06 用于运动机能亢进性运动障碍的治疗的vmat2抑制剂

Publications (1)

Publication Number Publication Date
CN106456629A true CN106456629A (zh) 2017-02-22

Family

ID=53264772

Family Applications (3)

Application Number Title Priority Date Filing Date
CN201580023821.XA Pending CN106456629A (zh) 2014-05-06 2015-05-06 用于运动机能亢进性运动障碍的治疗的vmat2抑制剂
CN202011483141.5A Pending CN112741836A (zh) 2014-05-06 2015-05-06 用于运动机能亢进性运动障碍的治疗的vmat2抑制剂
CN202011483135.XA Pending CN112741835A (zh) 2014-05-06 2015-05-06 用于运动机能亢进性运动障碍的治疗的vmat2抑制剂

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN202011483141.5A Pending CN112741836A (zh) 2014-05-06 2015-05-06 用于运动机能亢进性运动障碍的治疗的vmat2抑制剂
CN202011483135.XA Pending CN112741835A (zh) 2014-05-06 2015-05-06 用于运动机能亢进性运动障碍的治疗的vmat2抑制剂

Country Status (24)

Country Link
US (3) US20170071932A1 (enExample)
EP (3) EP3936130B1 (enExample)
JP (4) JP6635945B2 (enExample)
KR (5) KR20240011255A (enExample)
CN (3) CN106456629A (enExample)
AU (1) AU2015256012B2 (enExample)
CA (1) CA2947736C (enExample)
CY (1) CY1125058T1 (enExample)
DK (2) DK3936130T3 (enExample)
ES (2) ES2904526T3 (enExample)
FI (1) FI3936130T3 (enExample)
HR (2) HRP20240459T1 (enExample)
HU (2) HUE057839T2 (enExample)
IL (1) IL248745B (enExample)
LT (2) LT3936130T (enExample)
MX (1) MX387625B (enExample)
NZ (1) NZ725826A (enExample)
PL (2) PL3936130T3 (enExample)
PT (2) PT3936130T (enExample)
RS (2) RS65359B1 (enExample)
RU (1) RU2753740C2 (enExample)
SI (2) SI3936130T1 (enExample)
SM (2) SMT202200193T1 (enExample)
WO (1) WO2015171802A1 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110678181A (zh) * 2017-04-01 2020-01-10 阿德普蒂奥制药有限公司 (+)-α-二氢丁苯那嗪在治疗运动障碍中的用途
CN114679906A (zh) * 2019-08-23 2022-06-28 纽罗克里生物科学有限公司 向具有重度肾损伤的患者施用特定的vmat2抑制剂的方法
TWI832854B (zh) * 2018-04-25 2024-02-21 美商神經治療股份有限公司 丁苯那嗪經皮輸送裝置

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3368534T3 (da) * 2015-10-30 2021-02-15 Neurocrine Biosciences Inc Valbenazin-ditosylat og polymorfer deraf
DK3394057T3 (da) 2015-12-23 2022-04-11 Neurocrine Biosciences Inc Syntetisk fremgangsmåde til fremstilling af (S)-(2R,3R,11BR)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11B-hexahydro-1H-pyrido[2,1,-A]isoquinolin-2-yl 2-amino-3-methylbutanoat-di(4-methylbenzensulfonat)
US10442800B2 (en) 2016-06-29 2019-10-15 Crystal Pharmaceutical (Suzhou) Co., Ltd. Crystal forms of NBI-98854, preparation method and use thereof
TW202515564A (zh) * 2016-12-02 2025-04-16 美商紐羅克里生物科學有限公司 戊苯那嗪（valbenazine）於治療精神分裂症或情感性精神分裂症之用途
EP3568394A1 (en) 2017-01-10 2019-11-20 Sandoz AG Crystalline valbenazine free base
KR20230170136A (ko) 2017-01-27 2023-12-18 뉴로크린 바이오사이언시즈 인코퍼레이티드 특정 vmat2 억제제의 투여 방법
CA3054238A1 (en) 2017-02-27 2018-08-30 Sandoz Ag Crystalline forms of valbenazine salts
WO2018164996A1 (en) * 2017-03-06 2018-09-13 Neurocrine Biosciences, Inc. Dosing regimen for valbenazine
US20190111035A1 (en) * 2017-04-01 2019-04-18 Adeptio Pharmaceuticals Limited Pharmaceutical compositions
GB201705306D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
GB201705304D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
GB201705305D0 (en) * 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
GB201705302D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
GB201705303D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
CN110691596A (zh) * 2017-04-01 2020-01-14 阿德普蒂奥制药有限公司 药物组合物
WO2018200605A1 (en) * 2017-04-26 2018-11-01 Neurocrine Biosciences, Inc. Use of valbenazine for treating levodopa-induced dyskinesia
CA3076000A1 (en) 2017-09-21 2019-03-28 Neurocrine Biosciences, Inc. High dosage valbenazine formulation and compositions, methods, and kits related thereto
US20200230127A1 (en) 2017-10-10 2020-07-23 Neurocrine Biosciences, Inc. Methods for the Administration of Certain VMAT2 Inhibitors
KR20250070134A (ko) 2017-10-10 2025-05-20 뉴로크린 바이오사이언시즈 인코퍼레이티드 특정 vmat2 억제제의 투여 방법
CA3081709A1 (en) * 2017-11-08 2019-05-16 Yuhua Li Esters of dihydrotetrabenazine
KR102447769B1 (ko) 2017-12-26 2022-09-26 크리스탈 파마슈티컬 (쑤저우) 씨오., 엘티디. 발베나진 토실산염의 결정형 및 그 제조 방법 및 용도
GB201808464D0 (en) 2018-05-23 2018-07-11 Adeptio Pharmaceuticals Ltd Pharmaceutical compounds for use in treating huntington's disease
JOP20200298A1 (ar) 2018-06-14 2020-11-22 Neurocrine Biosciences Inc مركبات مثبطة لـ vmat2 وتركيبات وطرق تتعلق بها
SG11202100303QA (en) 2018-08-15 2021-02-25 Neurocrine Biosciences Inc Methods for the administration of certain vmat2 inhibitors
EP3860599B1 (en) 2018-10-04 2024-05-15 Adeptio Pharmaceuticals Limited (+)-alpha-dihydrotetrabenazine dosage regimen for treating movement disorders
EA202193012A1 (ru) * 2019-05-09 2022-03-02 Ньюрокрайн Байосайенсиз, Инк. Способы введения определенных ингибиторов vmat2
PE20240822A1 (es) 2021-03-22 2024-04-18 Neurocrine Biosciences Inc Inhibidores de vmat2 y metodos de uso

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101553487A (zh) * 2006-11-08 2009-10-07 纽罗克里生物科学有限公司 取代的3-异丁基-9,10-二甲氧基-1,3,4,6,7,11b-六氢-2H-吡啶并[2,1-a]异喹啉-2-醇化合物和与其相关的方法
WO2014047167A1 (en) * 2012-09-18 2014-03-27 Auspex Pharmaceuticals, Inc. Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010509336A (ja) * 2006-11-09 2010-03-25 ニューヨーク ユニバーシティ サンドイッチ材料の製造方法、ガラス／セラミック／ガラス複合構造物、ガラス／セラミック／ガラス、医科あるいは歯科補綴、およびガラス／ジルコニア／ガラスサンドイッチ材料
GB2462611A (en) 2008-08-12 2010-02-17 Cambridge Lab Pharmaceutical composition comprising tetrabenazine
US20110053866A1 (en) * 2008-08-12 2011-03-03 Biovail Laboratories International (Barbados) S.R.L. Pharmaceutical compositions
WO2011019956A2 (en) * 2009-08-12 2011-02-17 Biovail Laboratories International (Barbados) S.R.L. Pharmaceutical compositions
NZ591615A (en) 2008-09-18 2012-07-27 Auspex Pharmaceuticals Inc Benzoquinoline inhibitors of vesicular monoamine transporter 2
US20120003330A1 (en) * 2010-06-01 2012-01-05 Auspex Pharmaceuticals, Inc. Benzoquinolone inhibitors of vmat2
US9782398B2 (en) * 2014-02-07 2017-10-10 Neurocrine Biosciences, Inc. Pharmaceutical compositions comprising an antipsychotic drug and a VMAT2 inhibitor and uses thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101553487A (zh) * 2006-11-08 2009-10-07 纽罗克里生物科学有限公司 取代的3-异丁基-9,10-二甲氧基-1,3,4,6,7,11b-六氢-2H-吡啶并[2,1-a]异喹啉-2-醇化合物和与其相关的方法
WO2014047167A1 (en) * 2012-09-18 2014-03-27 Auspex Pharmaceuticals, Inc. Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
江文峰等: "氘代作用在药物研究中的应用", 《齐鲁药事》 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110678181A (zh) * 2017-04-01 2020-01-10 阿德普蒂奥制药有限公司 (+)-α-二氢丁苯那嗪在治疗运动障碍中的用途
TWI832854B (zh) * 2018-04-25 2024-02-21 美商神經治療股份有限公司 丁苯那嗪經皮輸送裝置
US12144899B2 (en) 2018-04-25 2024-11-19 Shinkei Therapeutics, Inc. Tetrabenazine transdermal delivery device
CN114679906A (zh) * 2019-08-23 2022-06-28 纽罗克里生物科学有限公司 向具有重度肾损伤的患者施用特定的vmat2抑制剂的方法

Also Published As

Publication number Publication date
EP3139925B1 (en) 2021-12-01
CA2947736A1 (en) 2015-11-12
MX387625B (es) 2025-03-18
RU2016147523A (ru) 2018-06-08
CN112741835A (zh) 2021-05-04
EP4389227A2 (en) 2024-06-26
PL3139925T3 (pl) 2022-03-21
WO2015171802A1 (en) 2015-11-12
SI3936130T1 (sl) 2024-05-31
JP2024153782A (ja) 2024-10-29
EP4389227A3 (en) 2024-09-04
CY1125058T1 (el) 2023-06-09
SMT202400199T1 (it) 2024-07-09
IL248745B (en) 2022-07-01
PT3936130T (pt) 2024-04-17
EP3139925A1 (en) 2017-03-15
KR20240011255A (ko) 2024-01-25
DK3936130T3 (da) 2024-03-25
JP6635945B2 (ja) 2020-01-29
KR20200133003A (ko) 2020-11-25
KR20160147044A (ko) 2016-12-21
CA2947736C (en) 2023-04-18
SI3139925T1 (sl) 2022-04-29
HRP20240459T1 (hr) 2024-06-21
HUE066361T2 (hu) 2024-07-28
US20200101063A1 (en) 2020-04-02
RS62782B1 (sr) 2022-01-31
FI3936130T3 (fi) 2024-04-23
ES2976207T3 (es) 2024-07-26
RU2016147523A3 (enExample) 2018-12-28
NZ725826A (en) 2023-05-26
RS65359B1 (sr) 2024-04-30
JP2019218407A (ja) 2019-12-26
EP3936130B1 (en) 2024-02-14
HUE057839T2 (hu) 2022-06-28
JP2017514850A (ja) 2017-06-08
AU2015256012B2 (en) 2020-07-23
US20170071932A1 (en) 2017-03-16
IL248745A0 (en) 2017-01-31
US20210196702A1 (en) 2021-07-01
LT3139925T (lt) 2022-01-25
PL3936130T3 (pl) 2024-06-10
KR20250029267A (ko) 2025-03-04
SMT202200193T1 (it) 2022-07-21
PT3139925T (pt) 2022-01-26
CN112741836A (zh) 2021-05-04
EP3936130A1 (en) 2022-01-12
JP2021191799A (ja) 2021-12-16
HRP20220025T1 (hr) 2022-04-01
MX2016014429A (es) 2017-04-06
AU2015256012A1 (en) 2016-11-24
ES2904526T3 (es) 2022-04-05
RU2753740C2 (ru) 2021-08-23
DK3139925T3 (da) 2021-12-20
KR20220140647A (ko) 2022-10-18
LT3936130T (lt) 2024-04-25

Similar Documents

Publication Publication Date Title
US20210196702A1 (en) Treatment of hyperkinetic movement disorders
US20190015396A1 (en) Vmat2 inhibitors for treating neurological diseases or disorders
US20250248969A1 (en) Combinations of monoamine oxidase inhibitors and serotonin receptor agonists and their therapeutic use
US11191758B2 (en) Use of selective serotonin 5-HT1A receptor agonists for treating side-effects of VMAT inhibitors
HK40111840A (en) Valbenazine dosage regimen for the treatment of hyperkinetic movement disorders
HK40067005A (en) Valbenazine dosage regimen for the treatment of hyperkinetic movement disorders
HK40067005B (en) Valbenazine dosage regimen for the treatment of hyperkinetic movement disorders
HK1235303A1 (en) Valbenazine dosage regimen for the treatment of hyperkinetic movement disorders
HK1235303B (en) Valbenazine dosage regimen for the treatment of hyperkinetic movement disorders
WO2016066687A1 (en) Losmapimod for treating copd
EP2255807A1 (en) Method of treating sleep disorders using the combination of eplivanserin and zolpidem

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20170222

RJ01 Rejection of invention patent application after publication